Safety, Tolerability and Behavioural Effects of Souroubea-Platanus in Healthy Volunteers
NCT ID: NCT03904511
Last Updated: 2020-02-11
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE1
Total Enrollment
45 participants
Study Classification
INTERVENTIONAL
Study Start Date
2019-05-15
Study Completion Date
2020-02-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Souroubea sympetala extracts have shown anxiolytic properties in animal models. Souroubea and its active principle betulinic acid appear to exert these effects by acting as an agonist for the benzodiazepine (BZD) binding site of the GABAA receptor with no withdrawal effects on food intake, locomotor activity, or other symptoms typically associated with BZD agonism. As such, this may offer a valuable source for an alternative anti-anxiety treatment.
The primary objective of this study is to (1) to evaluate the safety and tolerability of a single daily dose of an extract of a mixture of Souroubea spp. leaf and small branch material and Platanus spp. bark when administered orally over two weeks in healthy volunteers. Based on its safety in canine trials, we hypothesize that Souroubea-Platanus (SP) preparation will be well tolerated with adverse event profile similar to placebo.
The secondary objective is (2) to establish whether some of the anxiolytic properties of Souroubea-platanus seen in animal models will translate to human participants. We hypothesize that Souroubea-Platanus preparation will demonstrate anxiolytic and/or stress-reduction properties as indicated by salivary cortisol levels and self-report measures of anxiety.
The primary objective of this study is to (1) to evaluate the safety and tolerability of a single daily dose of an extract of a mixture of Souroubea spp. leaf and small branch material and Platanus spp. bark when administered orally over two weeks in healthy volunteers. Based on its safety in canine trials, we hypothesize that Souroubea-Platanus (SP) preparation will be well tolerated with adverse event profile similar to placebo.
The secondary objective is (2) to establish whether some of the anxiolytic properties of Souroubea-platanus seen in animal models will translate to human participants. We hypothesize that Souroubea-Platanus preparation will demonstrate anxiolytic and/or stress-reduction properties as indicated by salivary cortisol levels and self-report measures of anxiety.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Therapeutic Effect of an Herbal Medicine on Anxiety
NCT01178632
Anxiety Disorders
UNKNOWN
PHASE3
Efficacy and Safety Study of a IMSS Developed Phytopharmaceutical for the Treatment of Anxiety.
NCT03702803
Generalized Anxiety Disorder
UNKNOWN
PHASE2
Association of Passiflora Incarnata L; Crataegus Oxyacantha L and Salix Alba L. on Mild and Moderate Anxiety
NCT00794456
Anxiety Disorder
COMPLETED
PHASE3
Perceived Changes in Anxiety Symptom Burden During Treatment With Bryophyllum Pinnatum and Tolerability
NCT04825171
Anxiety Symptoms
COMPLETED
PHASE4
Evaluate the Beneficial Effects of an Oral Nutritional Supplement Based on Leonurus Cardiaca for the Improvement of Mood and Anxiety
NCT06954038
General Anxiety Disorder
NOT_YET_RECRUITING
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Background
Within Latin American indigenous communities tea brewed from fresh or dried crushed Souroubea leaves is used to treat Susto, a culture-bound syndrome resembling manifestations of Anxiety Disorders. Souroubea sympetala (Ss) leaf extract has shown to be effective as an anxiolytic in animal models, and betulinic acid (BA) is one of the active molecules responsible for mediating this effect.
Plant-based natural products are sought by many individuals as alternatives or supplements to standard medical care. As a result, more research is required in order to develop botanical treatments that are evidence-based, safe and guided by health practitioners. Souroubea-Platanus may offer such alternative.
Safety
Evidence suggests that Souroubea-Platanus was well tolerated in Beagles in a 28-day pilot study at 8x recommended dose, producing significant reductions in plasma cortisol 1h post-administration without any adverse reactions, except slightly reduced platelet count in 2 animals attributed to infection with Ehrlichia canis, likely contracted prior to the study onset. In a follow-up 16 beagles and up to 5x the recommended does for 28 days such decrease in platelet count was not observed, no there were any other adverse events. No adverse events have been reported in animals for the animal health product version of the drug (Zentrol) that has been on the market for 2 years. The naturalistic observations of Souroubea consumption suggest that it is safe for human use, however, this has not been established in a formal study. In addition, drug interactions have occurred with some herbal products, particularly those that strongly inhibit or induce CYP enzymes. As Souroubea may act on the BDZ binding site of the GABAA receptor, possible side-effects and symptoms similar to those associated with benzodiazepine anxiolytics are possible.
Clinical Relevance
The study has significant clinical relevance for anxiety and stress-related disorders and may lead to developing a new anxiolytic agent or supplement with more selective effects and reduced risks for the patients.
Overview of study design
Forty-five healthy adult volunteers will be enrolled in the single-center, randomized, double-blind, parallel group study. Power analysis revealed that to achieve a power of 0.80, with an estimated effect size of 0.40 (estimate based on rodent studies), a total sample size of 42 would be required. Accounting for approximately 10% predicted participant dropout rate per group, it is expected that 45 participants will be enrolled in the study.
Participants will be randomly assigned to one of the 3 treatment groups with 15 individuals in each for detecting a dose-response effect. Treatment groups will be either (a) 190mg extract (b) 380mg extract, or (c) inert placebo, all in identical vegicaps.
Capsules containing the placebo and the extracts will be produced under GMP conditions. In accordance with Health Canada guidelines, extract will conform to the acceptable limits for heavy metal and biological contamination. The placebo will consist of microcrystalline cellulose suitable for use in foods.
The capsules will be taken once a day in the morning with water for 2 consecutive weeks. The safety evaluations will be conducted at screening and repeated at the end of the 2-week study period. Adverse events will be evaluated after 1 week and 2 weeks of treatment and 1 week after discontinuation. The participants will be asked to maintain their regular lifestyle and diet during the study period so long as those habits do not violate the study exclusion criteria.
Participants will be asked to take the capsules at the same time every morning. Compliance will be facilitated by daily reminders by e-mail, text, or phone call and a review of the returned medication vials.
The participants will have 24-hour phone access to the study physician for emergencies.
Participant Compensation
Participants will be reimbursed for their time in participation, as well as for transportation and parking costs on prorated basis corresponding to minimal hourly wage.
Randomization and blinding
Blinded treatment will be used to reduce potential bias during data collection and evaluation of clinical endpoints. Participant numbers will be assigned in sequential order as participants enroll in the study. All participants will be asked to come in at the same time for all testing periods after screening (Days 1, 7, 14, and 21) in order to account for time-of-day effects on cortisol.
Participants will be assigned to one of the treatment groups according to a computer generated randomization schedule prepared by contracted pharmacy personnel. The randomization will be balanced by using permuted blocks. Pharmacy personnel will package and label study drug for each participant.
The study investigator or his/her designate and study participant will remain blind to the participants' group until the completion of the study. The blind should be broken only if in emergency requiring knowing the treatment status of the participant.
Study procedures
1. Baseline screening will include:
1. Medical history, physical examination, and vital signs, including temperature, heart rate, respiratory rate and blood pressure;
2. Mental status examination, including completion of the DSM-5 Self-Rated Level 1 Cross-Cutting Symptom Measure - Adult with follow-up on any items rated as present in at least mild degree;
3. Laboratory tests and urine drug screen as described below;
4. Serum pregnancy test for females of childbearing potential; must not be pregnant
2. Safety evaluations:
1. Each volunteer will provide a blood and urine sample in the morning, within 14 days before the start of the study (baseline), 7 days after the first dose, and on the last day of the study (day 14). Body weight will be measured at baseline and day 14. Physical examination including vital signs and inquiry of adverse events will be performed on days 7 and 14. Additional evaluation of adverse events will be done one week after discontinuation of the study drug. Vital signs will be monitored until 1 hour after administration of the first dose.
The following laboratory parameters will be measured:
* complete blood count: white blood cell (WBC) count with differential, red blood cell (RBC) count, hemoglobin, hematocrit and indices, platelet count;
* chemistry panel: glucose, calcium, electrolytes (sodium, potassium, chloride), BUN, creatinine, albumin, total protein, alkaline phosphatase, gamma glutamyl transferase, aspartate aminotransferase, alanine aminotransferase, bilirubin, creatine kinase;
* urinalysis will be standard, microscopic if indicated;
* salivary cortisol will be measured as a stress indicator.
Pregnancy testing in females will consist of a serum test (for convenience, since other blood samples are already being collected during screening; this should not normally require additional venipuncture).
Saliva samples will be collected using sterile saliva sample tubes. Blood and urine samples will be collected at the clinical laboratory. Blood samples will be drawn by venipuncture.
Records of health data identifying participants will be kept on record for 25 years before being destroyed; all records will be kept confidential during that time.
Behavioural evaluations
1. State-Trait Anxiety Inventory (STAI) on Days 1 (baseline and 1 hour post-dose), 7 and 14.
2. DSM-5 Self-rated Level 2 anxiety adult short form on Days 1, 7, and 14
3. Cortisol (physiological marker of stress): salivary concentration; analysis - difference between pre- and 1 h post dose on Day 1, max changes from baseline and group x time effects and interactions.
Data analysis
Statistical means and standard deviations will be calculated for each continuous variable. ANOVA followed by post hoc Tukey's test will be used to evaluate significant differences among dose groups and different days. A P-value of 0.05 will be considered as the level of significant difference in the analysis of the data. Behavioural variables will be analyzed using mixed effects ANOVA for repeated measures where appropriate.
Transformations for non-normality and/or corrective procedures will be applied if data is found to be non-normally distributed or otherwise in violation of the assumptions of the statistical tests.
STAI: the total sum scores (T-scores); analysis - max changes from baseline and group x time effects and interactions.
Cortisol: salivary concentration; analysis - difference between pre- and 1 h post dose on Day 1, max changes from baseline and group x time effects and interactions.
Safety evaluations will be based on the baseline to treatment-period differences in laboratory tests, physical examinations, vital signs and the incidence of adverse events.
Adverse events reporting
All adverse events (AE) regardless of casual relationship with investigational treatment will be recorded. An AE will be considered treatment-emergent if it is new in onset or aggravated in severity or frequency following administration of the investigational agent. All treatment emergent AE will be followed until resolution or a stable clinical endpoint.
Serious AE, e.g. any AE that is fatal, immediately life threatening, requires or prolongs hospitalization, causes permanent or significant disability will be reported to Health Canada and IRB and immediately addressed medically as appropriate.
Participants will be encouraged to report AEs spontaneously or in response to general, non-directed questioning. All treatment-emergent AEs will be recorded in the source document using medical terminology.
Within Latin American indigenous communities tea brewed from fresh or dried crushed Souroubea leaves is used to treat Susto, a culture-bound syndrome resembling manifestations of Anxiety Disorders. Souroubea sympetala (Ss) leaf extract has shown to be effective as an anxiolytic in animal models, and betulinic acid (BA) is one of the active molecules responsible for mediating this effect.
Plant-based natural products are sought by many individuals as alternatives or supplements to standard medical care. As a result, more research is required in order to develop botanical treatments that are evidence-based, safe and guided by health practitioners. Souroubea-Platanus may offer such alternative.
Safety
Evidence suggests that Souroubea-Platanus was well tolerated in Beagles in a 28-day pilot study at 8x recommended dose, producing significant reductions in plasma cortisol 1h post-administration without any adverse reactions, except slightly reduced platelet count in 2 animals attributed to infection with Ehrlichia canis, likely contracted prior to the study onset. In a follow-up 16 beagles and up to 5x the recommended does for 28 days such decrease in platelet count was not observed, no there were any other adverse events. No adverse events have been reported in animals for the animal health product version of the drug (Zentrol) that has been on the market for 2 years. The naturalistic observations of Souroubea consumption suggest that it is safe for human use, however, this has not been established in a formal study. In addition, drug interactions have occurred with some herbal products, particularly those that strongly inhibit or induce CYP enzymes. As Souroubea may act on the BDZ binding site of the GABAA receptor, possible side-effects and symptoms similar to those associated with benzodiazepine anxiolytics are possible.
Clinical Relevance
The study has significant clinical relevance for anxiety and stress-related disorders and may lead to developing a new anxiolytic agent or supplement with more selective effects and reduced risks for the patients.
Overview of study design
Forty-five healthy adult volunteers will be enrolled in the single-center, randomized, double-blind, parallel group study. Power analysis revealed that to achieve a power of 0.80, with an estimated effect size of 0.40 (estimate based on rodent studies), a total sample size of 42 would be required. Accounting for approximately 10% predicted participant dropout rate per group, it is expected that 45 participants will be enrolled in the study.
Participants will be randomly assigned to one of the 3 treatment groups with 15 individuals in each for detecting a dose-response effect. Treatment groups will be either (a) 190mg extract (b) 380mg extract, or (c) inert placebo, all in identical vegicaps.
Capsules containing the placebo and the extracts will be produced under GMP conditions. In accordance with Health Canada guidelines, extract will conform to the acceptable limits for heavy metal and biological contamination. The placebo will consist of microcrystalline cellulose suitable for use in foods.
The capsules will be taken once a day in the morning with water for 2 consecutive weeks. The safety evaluations will be conducted at screening and repeated at the end of the 2-week study period. Adverse events will be evaluated after 1 week and 2 weeks of treatment and 1 week after discontinuation. The participants will be asked to maintain their regular lifestyle and diet during the study period so long as those habits do not violate the study exclusion criteria.
Participants will be asked to take the capsules at the same time every morning. Compliance will be facilitated by daily reminders by e-mail, text, or phone call and a review of the returned medication vials.
The participants will have 24-hour phone access to the study physician for emergencies.
Participant Compensation
Participants will be reimbursed for their time in participation, as well as for transportation and parking costs on prorated basis corresponding to minimal hourly wage.
Randomization and blinding
Blinded treatment will be used to reduce potential bias during data collection and evaluation of clinical endpoints. Participant numbers will be assigned in sequential order as participants enroll in the study. All participants will be asked to come in at the same time for all testing periods after screening (Days 1, 7, 14, and 21) in order to account for time-of-day effects on cortisol.
Participants will be assigned to one of the treatment groups according to a computer generated randomization schedule prepared by contracted pharmacy personnel. The randomization will be balanced by using permuted blocks. Pharmacy personnel will package and label study drug for each participant.
The study investigator or his/her designate and study participant will remain blind to the participants' group until the completion of the study. The blind should be broken only if in emergency requiring knowing the treatment status of the participant.
Study procedures
1. Baseline screening will include:
1. Medical history, physical examination, and vital signs, including temperature, heart rate, respiratory rate and blood pressure;
2. Mental status examination, including completion of the DSM-5 Self-Rated Level 1 Cross-Cutting Symptom Measure - Adult with follow-up on any items rated as present in at least mild degree;
3. Laboratory tests and urine drug screen as described below;
4. Serum pregnancy test for females of childbearing potential; must not be pregnant
2. Safety evaluations:
1. Each volunteer will provide a blood and urine sample in the morning, within 14 days before the start of the study (baseline), 7 days after the first dose, and on the last day of the study (day 14). Body weight will be measured at baseline and day 14. Physical examination including vital signs and inquiry of adverse events will be performed on days 7 and 14. Additional evaluation of adverse events will be done one week after discontinuation of the study drug. Vital signs will be monitored until 1 hour after administration of the first dose.
The following laboratory parameters will be measured:
* complete blood count: white blood cell (WBC) count with differential, red blood cell (RBC) count, hemoglobin, hematocrit and indices, platelet count;
* chemistry panel: glucose, calcium, electrolytes (sodium, potassium, chloride), BUN, creatinine, albumin, total protein, alkaline phosphatase, gamma glutamyl transferase, aspartate aminotransferase, alanine aminotransferase, bilirubin, creatine kinase;
* urinalysis will be standard, microscopic if indicated;
* salivary cortisol will be measured as a stress indicator.
Pregnancy testing in females will consist of a serum test (for convenience, since other blood samples are already being collected during screening; this should not normally require additional venipuncture).
Saliva samples will be collected using sterile saliva sample tubes. Blood and urine samples will be collected at the clinical laboratory. Blood samples will be drawn by venipuncture.
Records of health data identifying participants will be kept on record for 25 years before being destroyed; all records will be kept confidential during that time.
Behavioural evaluations
1. State-Trait Anxiety Inventory (STAI) on Days 1 (baseline and 1 hour post-dose), 7 and 14.
2. DSM-5 Self-rated Level 2 anxiety adult short form on Days 1, 7, and 14
3. Cortisol (physiological marker of stress): salivary concentration; analysis - difference between pre- and 1 h post dose on Day 1, max changes from baseline and group x time effects and interactions.
Data analysis
Statistical means and standard deviations will be calculated for each continuous variable. ANOVA followed by post hoc Tukey's test will be used to evaluate significant differences among dose groups and different days. A P-value of 0.05 will be considered as the level of significant difference in the analysis of the data. Behavioural variables will be analyzed using mixed effects ANOVA for repeated measures where appropriate.
Transformations for non-normality and/or corrective procedures will be applied if data is found to be non-normally distributed or otherwise in violation of the assumptions of the statistical tests.
STAI: the total sum scores (T-scores); analysis - max changes from baseline and group x time effects and interactions.
Cortisol: salivary concentration; analysis - difference between pre- and 1 h post dose on Day 1, max changes from baseline and group x time effects and interactions.
Safety evaluations will be based on the baseline to treatment-period differences in laboratory tests, physical examinations, vital signs and the incidence of adverse events.
Adverse events reporting
All adverse events (AE) regardless of casual relationship with investigational treatment will be recorded. An AE will be considered treatment-emergent if it is new in onset or aggravated in severity or frequency following administration of the investigational agent. All treatment emergent AE will be followed until resolution or a stable clinical endpoint.
Serious AE, e.g. any AE that is fatal, immediately life threatening, requires or prolongs hospitalization, causes permanent or significant disability will be reported to Health Canada and IRB and immediately addressed medically as appropriate.
Participants will be encouraged to report AEs spontaneously or in response to general, non-directed questioning. All treatment-emergent AEs will be recorded in the source document using medical terminology.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Anxiety
Stress, Psychological
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
TREATMENT
Blinding Strategy
DOUBLE
Participants
Investigators
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Low Dose Souroubea-Platanus
190 mg souroubea-platanus preparation in vegicap. Administered once daily for 14 days.
Group Type
EXPERIMENTAL
Souroubea-Platanus Preparation
Intervention Type
OTHER
Extracts of S. Sympetala and P. occidentalis.
High Dose Souroubea-Platanus
380 mg souroubea-platanus preparation in vegicap. Administered once daily for 14 days.
Group Type
EXPERIMENTAL
Souroubea-Platanus Preparation
Intervention Type
OTHER
Extracts of S. Sympetala and P. occidentalis.
Placebo
Inert placebo in an identical vegicap to the experimental treatment groups. Administered once daily for 14 days.
Group Type
PLACEBO_COMPARATOR
Placebo
Intervention Type
OTHER
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Souroubea-Platanus Preparation
Extracts of S. Sympetala and P. occidentalis.
Intervention Type
OTHER
Placebo
Placebo
Intervention Type
OTHER
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Male and female participants aged 18-70 years
2. Females of childbearing potential must use reliable contraception during the study period; acceptable methods of birth control include all hormonal methods, IUDs, complete abstinence, effective physical barriers (e.g. condoms), or confirmed vasectomy of partner (if that information is volunteered by the participant)
3. Participants must be in good health status based on medical history and physical examination, including vital signs and clinical laboratory tests
4. Participants must refrain from taking any prescription or over the counter medication within the 14 days prior to the beginning of the study and during the study period
5. Participants must be non-smokers or light/occasional smokers (not more than 10 cigarettes per day)
6. Alcohol consumption should not exceed 3 drinks on any single day and no more than 7 drinks per week in women and no more than 4 drinks on any single day and no more than 14 drinks per week for men
7. BMI of 18.5-30 kg/m2 excluding markedly underweight and obese individuals
8. Participants must be willing to give written informed consent after the nature of the study has been fully explained
2. Females of childbearing potential must use reliable contraception during the study period; acceptable methods of birth control include all hormonal methods, IUDs, complete abstinence, effective physical barriers (e.g. condoms), or confirmed vasectomy of partner (if that information is volunteered by the participant)
3. Participants must be in good health status based on medical history and physical examination, including vital signs and clinical laboratory tests
4. Participants must refrain from taking any prescription or over the counter medication within the 14 days prior to the beginning of the study and during the study period
5. Participants must be non-smokers or light/occasional smokers (not more than 10 cigarettes per day)
6. Alcohol consumption should not exceed 3 drinks on any single day and no more than 7 drinks per week in women and no more than 4 drinks on any single day and no more than 14 drinks per week for men
7. BMI of 18.5-30 kg/m2 excluding markedly underweight and obese individuals
8. Participants must be willing to give written informed consent after the nature of the study has been fully explained
Exclusion Criteria
1. Participants demonstrating uncontrolled clinically significant physical disease or abnormal laboratory test results within 14 days prior to the start of the study
2. Participants with current or history of alcohol or drug use disorder
3. Participants with any history of significant drug super-sensitivity, anaphylaxis, or anaphylactic reaction
4. Participants taking prescription medication or OTC medication within 14 days prior to inclusion
5. Participants who have a history of any significant psychiatric disorder or currently significant psychiatric symptoms
6. Participants with a family history of serious mental illness in first-degree relatives
7. Participants in a situation or having any condition which, in the opinion of the investigator, may interfere with optimal participation in the study
8. Participants testing positive for amphetamine, cannabinoids, cocaine, barbiturates, benzodiazepines, opioids or hallucinogens
9. Use of other non-prescription natural health products with known anti-anxiety effects
10. Known allergy to any of the medicinal and non-medicinal ingredients in any conditions of the study
2. Participants with current or history of alcohol or drug use disorder
3. Participants with any history of significant drug super-sensitivity, anaphylaxis, or anaphylactic reaction
4. Participants taking prescription medication or OTC medication within 14 days prior to inclusion
5. Participants who have a history of any significant psychiatric disorder or currently significant psychiatric symptoms
6. Participants with a family history of serious mental illness in first-degree relatives
7. Participants in a situation or having any condition which, in the opinion of the investigator, may interfere with optimal participation in the study
8. Participants testing positive for amphetamine, cannabinoids, cocaine, barbiturates, benzodiazepines, opioids or hallucinogens
9. Use of other non-prescription natural health products with known anti-anxiety effects
10. Known allergy to any of the medicinal and non-medicinal ingredients in any conditions of the study
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Souroubea Botanicals Inc.
UNKNOWN
Sponsor Role
collaborator
University of Ottawa
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jakov Shlik
Clinical Director, OSI Clinic at The Royal
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jakov Shlik, MD
Role: PRINCIPAL_INVESTIGATOR
University of Ottawa
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Royal's Institute of Mental Health Research (IMHR) affiliated with the University of Ottawa
Ottawa, Ontario, Canada
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Canada
References
Explore related publications, articles, or registry entries linked to this study.
Bourbonnais-Spear N, Awad R, Merali Z, Maquin P, Cal V, Arnason JT. Ethnopharmacological investigation of plants used to treat susto, a folk illness. J Ethnopharmacol. 2007 Feb 12;109(3):380-7. doi: 10.1016/j.jep.2006.08.004. Epub 2006 Sep 10.
Reference Type
BACKGROUND
Crandon L. Why susto. Ethnology 1983;22:153-167.
Reference Type
BACKGROUND
Klein J. Susto: the anthropological study of diseases of adaptation. Soc Sci Med (1967). 1978 Jan;12(1B):23-8. No abstract available.
Reference Type
BACKGROUND
Rubel AJ. The epidemiology of a folk illness: Susto in Hispanic America. Ethnology 1964;3:268-283.
Reference Type
BACKGROUND
Signorini I. Patterns of fright: multiple concepts of susto in a Nahua-Ladino Community of the Sierra de Puebla (Mexico). Ethnology 1982;21:313-323.
Reference Type
BACKGROUND
Bourbonnais-Spear N. Ethnobotany and ethnopharmacology of Q'eqchi'Maya medicinal plants from southern Belize used for ethnopsychiatric and neurological purposes. University of Ottawa (Canada), 2005.
Reference Type
BACKGROUND
Puniani E, Cayer C, Kent P, Mullally M, Sanchez-Vindas P, Poveda Alvarez L, Cal V, Merali Z, Arnason JT, Durst T. Ethnopharmacology of Souroubea sympetala and Souroubea gilgii (Marcgraviaceae) and identification of betulinic acid as an anxiolytic principle. Phytochemistry. 2015 May;113:73-8. doi: 10.1016/j.phytochem.2014.02.017. Epub 2014 Mar 15.
Reference Type
BACKGROUND
Mullally M, Mimeault C, Rojas MO, Vindas PS, Garcia M, Alvarez LP, et al. A botanical extract of Souroubea sympetala and its active principle, betulinic acid, attenuate the cortisol response to a stressor in rainbow trout, Oncorhynchus mykiss. Aquaculture 2017;468:26-31.
Reference Type
BACKGROUND
Mullally M, Cayer C, Kramp K, Otarola Rojas M, Sanchez Vindas P, Garcia M, Poveda Alvarez L, Durst T, Merali Z, Trudeau VL, Arnason JT. Souroubea sympetala (Marcgraviaceae): a medicinal plant that exerts anxiolysis through interaction with the GABAA benzodiazepine receptor. Can J Physiol Pharmacol. 2014 Sep;92(9):758-64. doi: 10.1139/cjpp-2014-0213. Epub 2014 Jul 28.
Reference Type
BACKGROUND
Cayer C. In vivo behavioural characterization of anxiolytic botanicals: Souroubea sympetala. PhD Thesis. Masters Thesis submitted to the University of Ottawa, 2011.
Reference Type
BACKGROUND
Kessler RC, Soukup J, Davis RB, Foster DF, Wilkey SA, Van Rompay MI, Eisenberg DM. The use of complementary and alternative therapies to treat anxiety and depression in the United States. Am J Psychiatry. 2001 Feb;158(2):289-94. doi: 10.1176/appi.ajp.158.2.289.
Reference Type
BACKGROUND
Villalobos P, Baker J, Sanchez Vindas P, Durst T, Masic A, Arnason JT. Clinical Observations and Safety Profile of Oral Herbal Products, Souroubea and Platanus Spp; a Pilot-Toxicology Study in Dogs. Acta Vet (Beogr) 2014;64:269-275.
Reference Type
BACKGROUND
Masic A, Liu R, Simkus K, Wilson J, Baker J, Sanchez P, Saleem A, Harris CC, Durst T, Arnason JT. Safety evaluation of a new anxiolytic product containing botanicals Souroubea spp. and Platanus spp. in dogs. Can J Vet Res. 2018 Jan;82(1):3-11.
Reference Type
BACKGROUND
Liu R, Ahmed F, Cayer C, Mullally M, Carballo AF, Rojas MO, Garcia M, Baker J, Masic A, Sanchez PE, Poveda L, Merali Z, Durst T, Arnason JT. New Botanical Anxiolytics for Use in Companion Animals and Humans. AAPS J. 2017 Nov;19(6):1626-1631. doi: 10.1208/s12248-017-0144-y. Epub 2017 Sep 11.
Reference Type
BACKGROUND
Smith RD, Ristic M, Huxsoll DL, Baylor RA. Platelet kinetics in canine ehrlichiosis: evidence for increased platelet destruction as the cause of thrombocytopenia. Infect Immun. 1975 Jun;11(6):1216-21. doi: 10.1128/iai.11.6.1216-1221.1975.
Reference Type
BACKGROUND
Romero LE, Meneses AI, Salazar L, Jimenez M, Romero JJ, Aguiar DM, Labruna MB, Dolz G. First isolation and molecular characterization of Ehrlichia canis in Costa Rica, Central America. Res Vet Sci. 2011 Aug;91(1):95-97. doi: 10.1016/j.rvsc.2010.07.021. Epub 2010 Aug 17.
Reference Type
BACKGROUND
Miller NS, Gold MS. Benzodiazepines: a major problem. Introduction. J Subst Abuse Treat. 1991;8(1-2):3-7. doi: 10.1016/0740-5472(91)90021-2.
Reference Type
BACKGROUND
Mullally M, Kramp K, Cayer C, Saleem A, Ahmed F, McRae C, Baker J, Goulah A, Otorola M, Sanchez P, Garcia M, Poveda L, Merali Z, Durst T, Trudeau VL, Arnason JT. Anxiolytic activity of a supercritical carbon dioxide extract of Souroubea sympetala (Marcgraviaceae). Phytother Res. 2011 Feb;25(2):264-70. doi: 10.1002/ptr.3246.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2018005
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Efficacy and Tolerability Study to Treat Mild and Moderate Anxiety
NCT00944268
UNKNOWN
PHASE3
A Study of the Effectiveness of Electronic Interventions on the Standardized Prescription Benzodiazepines and Z-drugs
NCT03724669
COMPLETED
NA
Efficacy and Safety of Buspirone, Sustained-release Tablets, 15 mg in Patients With Autonomic Dysfunction Syndrome Accompanied by Vertigo
NCT05430217
COMPLETED
PHASE3
The Efficacy of a Herbal Supplement in the Prevention of PTSD
NCT03724448
COMPLETED
PHASE1
Psychological Mobile Interventions to Reduce Distress
NCT05294809
COMPLETED
NA
Ultrashort Cognitive Behavioral Intervention for Tokophobia- A Prospective Randomized Single Blinded Controlled Trial
NCT02972112
UNKNOWN
NA
St. John's Wort Vs. Placebo in Obsessive-Compulsive Disorder.
NCT00035438
COMPLETED
PHASE2
Randomized Trial of Adult Participants With Generalized Anxiety Disorder
NCT03829241
COMPLETED
PHASE3
Effects of Buspar on Depressive Symptom Improvement and Neuroprotection in Patients With Anxiety Disorder
NCT01546896
WITHDRAWN
PHASE4
Gelsemium Sempervirens in Anticipatory Anxiety
NCT00914329
COMPLETED
PHASE3
A 10-Week Study for Efficacy and Safety Study of Gabitril in the Treatment of Adults With Generalized Anxiety Disorder
NCT00236067
COMPLETED
PHASE3
Psychosocial and Medication Treatment for Anxiety in Alcoholism
NCT00248612
COMPLETED
PHASE2/PHASE3
The Effects of Orexin Antagonism on Fear Extinction in PTSD
NCT06788522
NOT_YET_RECRUITING
PHASE4
Effect of Baclofen to Prevent Post-Traumatic Stress Disorder
NCT05877807
COMPLETED
Evaluation of the Effects of Etifoxine 100 mg and Lorazepam 2 mg on Vigilance and Cognitive Functions in the Elderly
NCT02147548
COMPLETED
PHASE3
Sublingual Cannabidiol for Anxiety
NCT02548559
COMPLETED
PHASE2
St. John's Wort Versus Placebo in Social Phobia
NCT00035412
COMPLETED
PHASE2
Internet-delivered CBT for Anxiety Related to Asthma
NCT04230369
ACTIVE_NOT_RECRUITING
NA
Efficacy and Safety of Inhaled NC-107 As Compared to Placebo After 4 Weeks of Treatment in Patients with Anxiety
NCT06656806
NOT_YET_RECRUITING
EARLY_PHASE1
Xenon Inhalation for Treatment of Posttraumatic Stress Disorder
NCT03635827
UNKNOWN
PHASE2/PHASE3
A Long-Term Study Continuing on From Study 04-001-01 of an Experimental Medication in Adults With Anxiety Disorder
NCT00106860
COMPLETED
PHASE3
A 10-Week Efficacy and Safety Study of Gabitril in the Treatment of Adults With Generalized Anxiety Disorder
NCT00236015
COMPLETED
PHASE3
A Trial of the Effect of CVL-865 on Panic Symptoms Induced by Carbon Dioxide Inhalation in Healthy Subjects
NCT04592536
COMPLETED
PHASE1
Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive Compulsive Disorder
NCT04641143
COMPLETED
PHASE3
Comparison of Usual Care and Distraction (Tablet) in Children 3-5 Years Old
NCT05368961
COMPLETED
NA